Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

1,397 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Moderate Buy
11Ratings
9 Buy
1 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Months Forecast

Average Price Target

$100.10
▲(28.58% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $100.10 with a high forecast of $210.00 and a low forecast of $35.00. The average price target represents a 28.58% change from the last price of $77.85.
Highest Price Target$210.00Average Price Target$100.10Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Bank of America Securities
$35.00
Sell
-55.04%
Downside
Reiterated
Axsome shares could react positively to Relmada trial failure, says BofA09:1810/14/2210/1409:1810/14/2209:18Axsome shares could react positively to Relmada trial failure, says BofA
Truist Financial
$150.00
Buy
92.68%
Upside
Reiterated
Axsome Therapeutics price target raised to $150 from $100 at TruistAxsome Therapeutics price target raised to $150 from $100 at Truist
Cowen & Co.
$130.00
Buy
66.99%
Upside
Reiterated
Cowen reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA ApprovalCowen reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval
William Blair
Buy
Reiterated
We are still optimistic for approval of AXS-05 given the strength of the clinical data package presented publicly and the fact that if the FDA were to issue a CRL, the agency would have had multiple opportunities to do so by now , so why keep the review open so long past the original August 22, 2021, PDUFA date? Still, we acknowledge that this is a wait-and-see event, and if a CRL were eventually issued, this would restrict the company’s access to a $100 million financing tranche from the Hercules loan facility , which appears increasingly more important to fund operations moving forward.
UBS
$35.00
Sell
-55.04%
Downside
Reiterated
Axsome Therapeutics (AXSM) PT Lowered to $35 at BofA SecuritiesBofA Securities analyst Ashwani Verma lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $35.00 (from $37.00) while maintaining a Underperform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AXSM Financial Forecast

AXSM Earnings Forecast
Next quarter’s earnings estimate for AXSM is -$1.07 with a range of -$1.54 to -$0.72. The previous quarter’s EPS was -$1.07. AXSM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.51% of the time in the same period. In the last calendar year AXSM has Underperformed its overall industry.
Next quarter’s earnings estimate for AXSM is -$1.07 with a range of -$1.54 to -$0.72. The previous quarter’s EPS was -$1.07. AXSM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.51% of the time in the same period. In the last calendar year AXSM has Underperformed its overall industry.
AXSM Sales Forecast
Next quarter’s sales forecast for AXSM is $22.38M with a range of $16.79M to $30.50M. The previous quarter’s sales results were $16.85M. AXSM beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s sales forecast for AXSM is $22.38M with a range of $16.79M to $30.50M. The previous quarter’s sales results were $16.85M. AXSM beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
AXSM Analyst Recommendation Trends
In the current month, AXSM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXSM average analyst price target in the past 3 months is $100.10
In the current month, AXSM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXSM average analyst price target in the past 3 months is $100.10

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics’s 12-month average price target is $100.10.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics has 28.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics has a conensus rating of Moderate Buy which is based on 9 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Axsome Therapeutics’s price target?
            The average price target for Axsome Therapeutics is $100.10. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $210.00 ,the lowest forecast is $35.00. The average price target represents 28.58% Increase from the current price of $77.85.
              What do analysts say about Axsome Therapeutics?
              Axsome Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis